Table 1 Clinical characteristics of 148 patients by the LMR level at diagnosis
Characteristic | No. (%) | Low LMR group LMR ≤ 2.7 | High LMR group LMR > 2.7 |
|---|---|---|---|
Gender | |||
Male | 91 (61.5) | 22 (14.9) | 69 (46.6) |
Female | 57 (38.5) | 15 (10.1) | 42 (28.4) |
Age (year) | |||
> 60 | 18 (12.2) | 6 (4.1) | 12 (8.1) |
≤ 60 | 130 (87.8) | 31 (20.9) | 99 (66.9) |
B symptoms | |||
Absent | 65 (43.9) | 14 (9.5) | 51 (34.5) |
Present | 83 (56.1) | 23 (15.5) | 60 (40.5) |
Lugano stage | |||
I–II2 | 119 (80.4) | 22 (14.9) | 97 (65.5) |
III–IV | 29 (19.6) | 15 (10.1) | 14 (9.5) |
ECOG PS | |||
< 2 | 143 (96.6) | 35 (23.6) | 108 (73.0) |
≥ 2 | 5 (3.4) | 2 (1.4) | 3 (2.0) |
LDH | |||
Normal | 107 (72.3) | 23 (15.5) | 84 (56.8) |
Abnormal | 41 (27.7) | 14 (9.5) | 27 (18.2) |
IPI score | |||
0–2 | 137 (92.6) | 32 (21.6) | 105 (70.9) |
3–5 | 11 (7.4) | 5 (3.4) | 6 (4.1) |
Distant metastasis | |||
Yes | 97 (65.5) | 22 (14.9) | 65 (43.9) |
No | 51 (35.5) | 15 (10.1) | 36 (24.3) |
Chemotherapy regimen | |||
DIE-L | 59 (39.9) | 45 (30.4) | 14 (9.5) |
GDP-L | 37 (25.0) | 28 (18.9) | 9 (6.1) |
CHOP-L | 22 (14.9) | 17 (11.5) | 5 (3.4) |
SMILE | 19 (12.8) | 13 (8.8) | 6 (4.1) |
P-Gemox | 6 (4.1) | 4 (2.7) | 2 (1.4) |